These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12888806)

  • 1. Celebrating novel cancer drugs.
    Weiss RA
    Br J Cancer; 2003 Aug; 89(3):425. PubMed ID: 12888806
    [No Abstract]   [Full Text] [Related]  

  • 2. [New oncological drugs].
    Pyrhönen S
    Duodecim; 2000; 116(24):2841-52. PubMed ID: 12077890
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
    Ratain MJ; Eckhardt SG
    J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
    [No Abstract]   [Full Text] [Related]  

  • 4. Enrichment designs: efficiency in development of cancer treatments.
    Temple RJ
    J Clin Oncol; 2005 Aug; 23(22):4838-9. PubMed ID: 15983397
    [No Abstract]   [Full Text] [Related]  

  • 5. Vitamin C as a cancer treatment: state of the science and recommendations for research.
    Tamayo C; Richardson MA
    Altern Ther Health Med; 2003; 9(3):94-101. PubMed ID: 12776480
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer research. As questions grow, Duke halts trials, launches investigation.
    Couzin-Frankel J
    Science; 2010 Aug; 329(5992):614-5. PubMed ID: 20688986
    [No Abstract]   [Full Text] [Related]  

  • 7. The convergence of cancer prevention and therapy in early-phase clinical drug development.
    Abbruzzese JL; Lippman SM
    Cancer Cell; 2004 Oct; 6(4):321-6. PubMed ID: 15488755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials referral resource. Clinical trials of MGI-114.
    Murgo A; Cannon DJ; Blatner G; Cheson BD
    Oncology (Williston Park); 1999 Feb; 13(2):233, 237-8. PubMed ID: 10079472
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting of cancer energy metabolism.
    Rodríguez-Enríquez S; Marín-Hernández A; Gallardo-Pérez JC; Carreño-Fuentes L; Moreno-Sánchez R
    Mol Nutr Food Res; 2009 Jan; 53(1):29-48. PubMed ID: 19123180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 13. BMS-247550 Bristol-Myers Squibb/GBF.
    Lin N; Brakora K; Seiden M
    Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
    Bell IM
    J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
    [No Abstract]   [Full Text] [Related]  

  • 15. Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside?
    Zhao Y; Neuzil J; Wu K
    Mol Nutr Food Res; 2009 Jan; 53(1):129-39. PubMed ID: 19072740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of curcumin in cancer therapy.
    Shishodia S; Chaturvedi MM; Aggarwal BB
    Curr Probl Cancer; 2007; 31(4):243-305. PubMed ID: 17645940
    [No Abstract]   [Full Text] [Related]  

  • 17. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 4.
    Eccles SA
    IDrugs; 2007 Dec; 10(12):844-7. PubMed ID: 18041676
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer drugs: restrictions recommended.
    Swinbanks D
    Nature; 1989 Dec 21-28; 342(6252):843. PubMed ID: 2687697
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
    Colevas AD; Scharf O; Schoenfeldt M
    Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
    [No Abstract]   [Full Text] [Related]  

  • 20. [The introduction of new drugs from the basic research to clinical application--issues in the drug development].
    Watanabe T; Saijo N
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():289-91. PubMed ID: 7986105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.